International Cardio-Oncology Society (ICOS) shared a post on X about a recent article by Joerg Herrmann et al, published in JAMA Oncology:
“Hot off the presses
Immune Checkpoint Inhibitor (ICIs) treatments are known to potentially cause harm to the heart, particularly through conditions like myocarditis. Today in JAMA Oncology, we stressed the importance of interdisciplinary collaboration as the best way to mitigate effects and protect the hearts of cancer patients.”
Title: Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
Authors: Joerg Herrmann, Ana Barac, Joseph Carver, Richard K. Cheng, Andres Daniele, Susan Dent, Elena Deych, Dae Hyun Lee, Daniel Lenihan, Darryl P. Leong, Jennifer Liu, Teresa Lopez-Fernandez, Alexander R. Lyon, Michael Fradley, Ariane V. S. Macedo, Meghan J. Mooradian, Anju Nohria, Charles Porter, Tienush Rassaf, Giselle Suero-Abreu, Aaron L. Sverdlov, Paaladinesh Thavendiranathan, Tomas G. Neilan, Joshua D. Mitchell
Read the Full Article on JAMA Oncology
Joshua Mitchell, Director of Cardio-Oncology Center of Excellence at Washington University School of Medicine in St. Louis, shared this post, adding:
“I am always in awe of the team we have on the International Cardio-Oncology Society Scientific and Research Committee. Such a fantastic group of international collaborators.
Really enjoyed working on this position statement with them. Great content in the manuscript and supplement!”
More posts featuring ICOS.